Document:

<PAGE>

                                                                   EXHIBIT 10.19

                  *** CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
                  DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED
                  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
                  PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER 17
                  C.F.R. SECTIONS 200.80(B)(4), 200.83 AND 230.406.

                         RESEARCH AND LICENSE AGREEMENT

         This Agreement is entered into and effective as of October 10, 2002
(the "Effective Date") by and between the following parties: Sequoia Sciences,
Inc. ("SEQUOIA"), 11199 Sorrento Valley Road, Suite H, San Diego, California
92121, and Anadys Pharmaceuticals, Inc. ("ANADYS"), 9050 Camino Santa Fe, San
Diego, CA 92121.

         WHEREAS, SEQUOIA has proprietary collections of drug-like compounds
isolated from plants for drug discovery research, and

         WHEREAS, ANADYS wishes to screen these drug-like compounds in its
proprietary biological assays with the intent of discovering novel,
biologically-active compounds for development into commercial therapeutic
products.

         NOW, THEREFORE, the parties under the terms and conditions specified
herein agree as follows:

                                 1. DEFINITIONS

         1.1      "Access Election" shall mean a notification from ANADYS to
SEQUOIA that ANADYS desires to obtain exclusive rights to and full ownership of
an Active Compound identified in such notification, as more fully set forth in
Section 2.4.1.

         1.2      "Active Samples" shall mean Samples supplied by SEQUOIA and
identified by ANADYS as having activity in ANADYS assays, at Anadys' sole
discretion.

         1.3      "Active Compound" shall mean an individual compound found
within an Active Sample that is provided by SEQUOIA to ANADYS that has
biological activity in ANADYS assays.

         1.4      "Affiliate" shall mean any person, organization, corporation,
or other business entity controlled by, controlling, or under common control
with a Party. As used in this Section 1.4, "control" means that an entity owns,
directly or indirectly, at least fifty percent (50%) of the voting stock or
other ownership interest of another entity, or has the actual ability to control
and direct the management of another entity, whether by contract or otherwise.

         1.5      "Anadys Corporate Event" shall mean (i) the merger or
consolidation of ANADYS with another corporation through either a merger, stock
purchase or sale or asset purchase or sale, (ii) the acquisition by ANADYS of a
substantial amount of assets or capital stock of another corporation through
either a stock purchase, stock exchange, cash transaction or asset exchange,
(iii) a reorganization of the business of ANADYS in such as way as to
fundamentally alter the business plan of ANADYS as in effect as of the Effective
Date of this Agreement, or (iv) a liquidation, dissolution or winding up of
ANADYS, either voluntary or involuntary; provided that any such event described
in (i), (ii), (iii) or (iv) above is approved by the ANADYS Board of Directors.

                                       1
<PAGE>

         1.6      "Analog" shall mean a compound made under a medicinal
chemistry effort that is focused on structure-function relationships, which
compound (a) shares common structure with an Active Compound for which an Access
Election has been made and (b) has been developed with the goal of demonstrating
activity against the same target(s) as the Active Compound from which it was
derived and actually demonstrates such activity. An Analog shall be determined
to share a common structure with an Active Compound if such Analog and such
Active Compound are both subject to claims within the same ANADYS patent
application which discloses a common structure.

         1.7      "Biological Material" shall mean plants, samples of plants,
plant parts such as roots, leaves, flowers, wood, bark, fruit, seeds, and any
other material of plant origin that are provided to Anadys by Sequoia under the
terms of this Agreement.

         1.8      "Confidential Information" shall mean data, databases,
figures, chemical structures, patent applications, documents, information
disclosed orally and subsequently reduced to writing, and includes
correspondence, memoranda, notes, reports and e-mail, information constituting
intellectual property, and any other information collected, developed or
prepared by the Parties pursuant to this Agreement.

         1.9      "Drug-like Compounds" shall mean compounds from plants with
average molecular weights less than 400 daltons determined by (+) ESI mass
spectrometry and approximate log Ps less than 5 and greater than 0 determined by
the retention times of compounds within the Samples during HPLC/ELSD analysis.

         1.10     "Exclusivity Period" shall mean, with respect to an Active
Sample or an Active Compound, the time period set forth in Section 2.7.1. or
2.7.2, as applicable, plus any extensions thereof, during which SEQUOIA shall
not provide such Active Sample or Active Compound or any rights thereto to any
third party, nor offer or negotiate with any third party to supply or grant
rights to such Active Sample or Active Compound.

         1.11     "FTE" or "Full-time Equivalent" shall mean a full-time
employee of SEQUOIA that possesses qualifications to successfully complete the
research described in Sections 2.2.1, 2.3.1, 2.3.2, and 2.5.

         1.12     "ANADYS Proprietary Rights" shall mean Patents, copyrights,
trademarks, trade secrets and other intellectual property rights, know-how or
processes, whether or not patentable, owned or controlled by ANADYS.

         1.13     "Net Sales" shall mean, in relation to a Product, (i) the
gross amount received by ANADYS, or its Affiliates or its sublicensees for sales
of Product to third parties less taxes (value added or sales taxes, government
mandated exceptional taxes and other taxes linked to the gross sales amount),
discounts, allowances, credits for returns, rejections or recalls, rebates
(price reductions, rebates to social and welfare systems, charge backs or
reserves for chargebacks, cash sales incentives, government mandated rebates and
similar types of rebates), import duties and other governmental charges or
tariffs, and insurance minus (ii) [...***...] percent ([...***...]%)

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       2
<PAGE>

of the gross amount received for Product in lieu of the following deductions
that are not usually accounted for or deducted on a product-by-product basis:
cash discounts, discounts granted later than at the time of invoicing, sales
commissions, outward freights, postage charges, packaging materials for dispatch
of goods, bad debt, transportation insurance charges and customs duties and
other governmental charges. Notwithstanding anything else in this Section 1.13,
amounts received by Anadys or its Affiliates or sublicensees for the sale of
Products among Anadys and its Affiliates or sublicensees for resale shall not be
included in the computation of Net Sales hereunder. In the event any Product is
sold in combination with other active functional ingredients (a "Combination
Product"), the Net Sales for Combination Products in a particular country, shall
be determined by multiplying the Net Sales for each such Combination Product by
a fraction, the numerator of which shall be the established market price for the
Product(s) contained in the Combination Product and the denominator of which
shall be the sum of the established market prices for the Product(s) plus the
established market prices for the other pharmaceutically active agents or
ingredients contained in the Combination Product. When such separate market
prices are not established in that country, then the Parties shall negotiate in
good faith to determine a fair and equitable method of calculating Net Sales in
that country for the Combination Product in question with the goal of
determining the appropriate percentage value represented by the Product and the
other pharmaceutically active agents or ingredients.

         1.14     "Novel Discoveries Date" shall mean the date on which the last
to occur of the following criteria are achieved for two (2) distinct compounds
against at least two (2) separate targets: 1.) Anadys identifies novel
biological activity of an individual compound, 2.) Sequoia elucidates the
chemical structure of this active compound which has a molecular weight less
than 500 daltons and a log P less 5, and 3) the results of a CAS search on this
compound does not yield information detailing the biological activity
demonstrated by ANADYS.

         1.15     "Party" (and collectively "Parties") shall mean SEQUOIA or
ANADYS.

         1.16     "Patent" or "Patents" shall mean (a) patent applications
(including provisional applications and applications for certificates of
invention); (b) any patents issuing from such patent applications (including
certificates of invention); (c) all patents and patent applications worldwide
based on, corresponding to, or claiming the priority date(s) of any of the
foregoing; (d) any reissues, substitutions, confirmations, registrations,
validations, re-examinations, additions, continuations, continued prosecution
applications, continuations-in-part, requests for continued examination, or
divisionals of or to any of the foregoing; and (e) term extension or other
governmental action which provide exclusive rights to a Product beyond the
original patent expiration date.

         1.17     "Phase 2" shall mean the period under this Agreement that will
commence either (i) automatically, and without further action by either party,
upon the occurrence of the Novel Discoveries Date (if it occurs) or (ii) upon
the election by ANADYS within three hundred sixty five (365) days of the
Effective Date by giving at least thirty (30) days written notice to SEQUOIA of
its desire to so commence Phase II, and which will end upon the expiration or
termination of this Agreement.

                                       3
<PAGE>

         1.18     "Phase 2 Commencement Date" shall mean the date on which
Phase 2 commences.

         1.19     "Pilot Study" shall mean the period under this Agreement
commencing on the Effective Date and terminating on the first to occur of the
Novel Discoveries Date and the expiration or termination of this Agreement.

         1.20     "Product" shall mean a product containing an Active Compound
or Analog sold and given to a patient for the treatment or prevention of human
or animal disease, diagnosis of a disease, or any research use.

         1.21     "Samples" shall mean samples of approximately one to five
Drug-like Compounds determined by (+) ESI mass spectrometry and evaporative
light scattering detection (ELSD) which have been isolated from a taxonomically
diverse collection of plants by SEQUOIA.

         1.22     "SEQUOIA Proprietary Rights" shall mean Patents, copyrights,
trademarks, trade secrets and other intellectual property rights, know-how or
processes, whether or not patentable, owned or controlled by SEQUOIA.

                        2.       DRUG DISCOVERY RESEARCH

         2.1      Primary Screening.

                  2.1.1    SEQUOIA will deliver Samples suitable for
high-throughput screening to ANADYS pursuant to the terms and conditions set
forth in Section 2.6. The Samples will be delivered in 384 well microtiter
plates. Each well in rows 1 through 12 and 15 through 24 in the microtiter
plates will have approximately [...***...] ([...***...]) micrograms of Sample
determined by evaporative light scattering detection. Rows 13 and 14 of the 384
well microtiter plates will not contain Sample.

                  2.1.2    ANADYS will screen these Samples in two or more of
its assays. ANADYS will have complete discretion at selecting the assays used to
screen the Samples and shall be free to utilize either internal or partnered
resources, included the targets, provided that the Samples are not transferred
to a third party without the prior written permission of SEQUOIA.

                  2.1.3    ANADYS will provide written notification to SEQUOIA
of the Samples that exhibit activity in its assays, identifying such Samples as
Active Samples. During the Pilot Period, ANADYS will provide the first such
written notification within ninety (90) days of receipt of the Samples. At no
time during the term of this Agreement will ANADYS be under any obligation to
disclose to SEQUOIA the identity of the targets against which it screens the
Samples. ANADYS will, however, label such targets with a code name identifier
and will provide written notification to SEQUOIA of each target that identify
each Active Sample via

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       4
<PAGE>

such unique identifier. ANADYS shall be automatically granted an Exclusivity
Period on Active Samples pursuant to the terms of Section 2.7.

         2.2      Isolation and Identification of Active Compounds.

                  2.2.1    SEQUOIA will isolate approximately [...***...]
([...***...]) to [...***...] ([...***...]) micrograms of each compound it
detects and quantifies by evaporative light scattering detection in the Active
Samples. SEQUOIA will deliver these isolated compounds to ANADYS.

                  2.2.2    If Phase 2 is triggered, SEQUOIA will isolate
compounds from at least [...***...] ([...***...]) Active Samples within twelve
(12) months of the Phase 2 Commencement Date, provided that at least [...***...]
([...***...]) Active Samples have been identified in Section 2.1.3.
Notwithstanding the foregoing, if Anadys does not identify at least [...***...]
([...***...]) Active Samples within twelve (12) months from the Phase 2
Commencement Date, the parties shall have an additional six (6) month period
during which (i) Anadys will continue to attempt to identify Active Samples, and
(ii) Sequoia will continue to conduct the work to isolate compounds from at
least [...***...] ([...***...]) Active Samples, provided that at least
[...***...] ([...***...]) Active Samples have been identified in Section 2.1.3
within (18) months from the Phase 2 Commencement Date.

                  2.2.3    ANADYS will screen these compounds isolated by
SEQUOIA in its assays to identify which compound(s) exhibits the biological
activity.

                  2.2.4    ANADYS will provide written notification to SEQUOIA
of the compounds that exhibit biological activity in ANADYS assays, identifying
such compounds as Active Compounds. ANADYS shall be automatically granted an
Exclusivity Period on Active Compounds pursuant to the terms of Section 2.7.

         2.3      Structure Elucidation and Additional Testing of the Active
Compounds.

                  2.3.1    SEQUOIA will elucidate the chemical structures of the
Active Compounds and deliver this information to ANADYS. If Phase 2 is
commenced, Sequoia will elucidate at least [...***...] ([...***...]) chemical
structures of Active Compounds, provided that at least [...***...] ([...***...])
Active Compounds have been identified pursuant to Section 2.2.4, and deliver
this information to ANADYS within twelve (12) months of the Phase 2 Commencement
Date. Notwithstanding the foregoing, if Anadys does not identify at least
[...***...] ([...***...]) Active Compounds within twelve (12) months from the
Phase 2 Commencement Date, the parties shall have an additional six (6) month
period during which (i) Anadys will continue to attempt to identify Active
Compounds, and (ii) Sequoia will continue to conduct the work to elucidate at
least [...***...] ([...***...]) chemical structures of Active Compounds,
provided that at least [...***...] ([...***...]) Active Compounds have been
identified pursuant to Section 2.2.4 within (18) months from the Phase 2
Commencement Date.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       5
<PAGE>

                  2.3.2    SEQUOIA will deliver approximately [...***...]
([...***...]) to [...***...] ([...***...]) micrograms of each Active Compound to
ANADYS for additional biological testing. These Active Compounds will have
purities greater than [...***...]%, as confirmed by HPLC / ELSD.

                  2.3.3    ANADYS will evaluate the dose response of each Active
Compound and the biological activity of each Active Compound in secondary
screens. ANADYS will provide written notification to SEQUOIA describing which
Active Compounds it determines, in its sole discretion, warrant additional
biological evaluation.

         2.4      Access Election of an Active Compound by ANADYS.

                  2.4.1    At any time during the Exclusivity Period of any
particular Active Compound, ANADYS, in its sole discretion, may make an Access
Election for that Active Compound by written notification to SEQUOIA. Upon such
Access Election, all rights, title, and interest in and to the Active Compound,
its isolation, purification, synthesis, its uses, and any inventions, data, or
discoveries shall be automatically assigned from SEQUOIA to ANADYS. ANADYS shall
be entitled to make an Access Election for any Active Compound according to the
payment provisions in Section 5.3, provided that ANADYS is in compliance with
the payment provisions in Section 6.1.

                  2.4.2    SEQUOIA shall cooperate with ANADYS, as requested, to
assist ANADYS in obtaining intellectual property protection relating to all
Active Compounds that are the subject of an Access Election, and shall execute
such documents, make such oaths, and in general provide all other reasonable
assistance to ANADYS to permit ANADYS to perfect its title in all such Active
Compounds and secure intellectual property protection in all such Active
Compounds in all countries. SEQUOIA shall have thirty (30) days to review the
claims and notify ANADYS of any issues relating to claim scope, unless the
Parties agree to a shorter period in light of patentability consideration.

         2.5      Isolation of Additional Quantities of Active Compounds. After
an Access Election has been made for an Active Compound, ANADYS may request in
writing the isolation of additional quantities of Active Compounds by SEQUOIA.
SEQUOIA will isolate additional quantities of these Active Compounds. The
amounts and purities of the Active Compounds requested by ANADYS and the timing
of their delivery will be mutually determined by ANADYS and SEQUOIA at the FTE
rate set forth in Section 5.2.

         2.6      Delivery of Samples, Active Samples, and Active Compounds to
ANADYS.

                  2.6.1    Delivery of Samples to ANADYS During Pilot Study. By
October 28, 2002 and pursuant to the provisions of Sections 2.1.1 and 6.1,
SEQUOIA will deliver approximately [...***...] to ANADYS.

                  2.6.2    Delivery of Samples to ANADYS During Phase 2. In the
event that the Phase 2 Commencement Date occurs, then within sixty (60) days of
the Phase 2 Commencement

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       6
<PAGE>

Date and pursuant to the provisions of Sections 2.1.1 and 6.1, SEQUOIA will
deliver an additional [...***...] Samples to ANADYS.

                  2.6.3    Deliveries to ANADYS. All Samples, Active Samples,
Active Compounds, or Biological Material under this Agreement will be delivered
to Anadys Pharmaceuticals, 9050 Camino Santa Fe, San Diego, CA 92121. Any
changes in the shipping address will be provided in writing from ANADYS to
SEQUOIA.

         2.7      Exclusivity Periods.

                  2.7.1    Exclusivity Periods for Active Samples. The
Exclusivity Period for each Active Sample identified by ANADYS in Section 2.1.3
shall occur automatically for a period of one year from the date of notification
or until the Exclusivity Period expires for an Active Compound identified from
such Active Sample in Section 2.2.4, whichever is shorter; provided, however,
that ANADYS may remove an Active Sample from exclusivity at any time by
providing written notification to SEQUOIA of its election to so remove the
specified Active Sample from exclusivity. An Exclusivity Period on an Active
Sample may be extended upon request by ANADYS to SEQUOIA, which shall not be
unreasonably withheld, to identify the Active Compound within each such Active
Sample considering commercially reasonable timelines. During the term of this
Agreement, the provisions of this Section 2.7.1 will apply to a maximum of
[...***...] ([...***...]) Active Samples at any given time, with any Active
Samples that have been removed from exclusivity pursuant to this Section 2.7.1
not counting towards such [...***...] ([...***...]) Active Sample maximum.

                  2.7.2    Exclusivity Periods for Active Compounds. The
Exclusivity Period for each Active Compound identified by ANADYS in Section
2.2.4 shall begin automatically upon notification by ANADYS and end one hundred
twenty (120) days after the later to occur of (a) receipt by ANADYS of the
Active Compound pursuant to the quantity requirements in Section 2.3.2 and (b)
receipt by ANADYS of the structure elucidation information with respect to such
Active Compound pursuant to Section 2.3.1. The Exclusivity Period of an Active
Sample from which the Active Compound originated is extended under the
Exclusivity Period of the Active Compound in this Section 2.7.2.

                  2.7.3    Prior Third Party Requests for Exclusivity. ANADYS
acknowledges that third parties have access to the same Samples provided to
ANADYS for initial screening pursuant to Section 2.1. During the term of this
Agreement, if any third parties make requests for information and material from
SEQUOIA in writing and pursuant to a written agreement that is in effect as of
the Effective Date of this Agreement, to obtain exclusivity to Samples or
compounds therein, prior to any request by ANADYS, SEQUOIA may be unable to
provide information, material and exclusivity to ANADYS. ANADYS will, however,
have unconditional priority for exclusivity with respect to any Samples or
compounds therein over any third parties that enter into agreements with SEQUOIA
subsequent to the Effective Date of this Agreement. If ANADYS requests
information, material or exclusivity with respect to a Sample and SEQUOIA is
unable to provide information, material or exclusivity due to a preexisting
obligation to a third party, SEQUOIA will so advise ANADYS at the time such
request is made.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       7
<PAGE>

                  2.7.4    Third Party Intellectual Property Rights. The Parties
expressly understand and agree that SEQUOIA can transfer and convey, and agrees
to transfer and convey to ANADYS, only the Patent, know-how and trade secret
ownership rights, if any, SEQUOIA may have in any Samples or compounds therein.
SEQUOIA cannot and does not represent and/or warrant that a third party does not
already have, or that it may not obtain at some future date, patent ownership
rights to compounds within the Samples as of the Effective Date or at any time
in the future. SEQUOIA is not currently aware of the existence of any such third
party rights, but hereby agrees that to the extent SEQUOIA becomes aware of any
such third party rights, either through SEQUOIA'S efforts or through the efforts
of one of its contracting partners, it shall disclose on a confidential basis
the same to ANADYS. Nothing in this Section 2.7, however, shall be deemed to
require SEQUOIA to undertake an investigation of the existence of any such third
party rights now or at any time in the future with respect to Samples or Active
Compounds that are not the subject of an Access Election.

         2.8      Recollection of Biological Material.

                  2.8.1    Sourcing Through Sequoia's Collaborator for
Recollection. Upon request by ANADYS for additional samples of Biological
Materials for the uses described in this Agreement, SEQUOIA shall have the right
to first arrange through its collaborators to recollect the Biological Material
from which the Active Compound was obtained. Any agreement between the Parties
with respect to such recollection, including provisions relating to cost,
timing, quantities and the like, will be upon mutually agreeable terms which are
approved by Anadys and will further specify that ANADYS will bear all
agreed-upon costs associated with recollection of Biological Material and with
the preparation of the Active Compound by SEQUOIA. The Parties further agree
that SEQUOIA may isolate the desired Active Compounds for ANADYS or send the
bulk Biological Material to ANADYS for processing, at ANADYS's option.

                  2.8.2    Terms for Obtaining Biological Materials. ANADYS
shall not import, recollect or obtain in any way Biological Material, through
SEQUOIA'S collaborators, for research, development, manufacturing, or sale,
without the approval of SEQUOIA, which approval shall not be unreasonably
withheld. The fees charged to ANADYS by SEQUOIA (or its collaborators, as
appropriate) shall be commercially reasonable relative to the cost of obtaining
the Biological Materials, in appropriate quantities, from other sources. Should
such terms and costs offered by SEQUOIA not be better than those from another
source, then ANADYS will be free to obtain Biological Material from sources
other than SEQUOIA or its collaborator. Nothing herein shall prevent ANADYS from
developing or manufacturing Active Compounds, Analogs, or Products from sources
other than Biological Materials.

         2.9      Compliance with International Biodiversity Regulations

                  2.9.1    Adherence to Regional and National Laws. SEQUOIA
shall adhere to the 1993 Convention on Biological Diversity (CBD), the 1973
Convention on International Trade in Endangered Species of Wild Fauna and Flora
(CITES), and other regional and national laws and

                                       8
<PAGE>

policies concerning biodiversity, and will endeavor to minimize environmental
impacts of collecting Biological Materials. Relevant provisions of the CBD
include: the sovereign rights of states over their biological resources; the
concern that biological diversity is being significantly reduced by certain
human activities; the need to provide additional scientific information about
biological diversity that may contribute to its conservation and sustainable use
of biological diversity; the need to promote fair and equitable sharing of the
benefits arising out of the utilization of genetic resources, including benefits
that arise from traditional knowledge; and the need to respect and maintain the
knowledge and practices of indigenous communities that are relevant for the
conservation and sustainable use of biological diversity.

                  2.9.2    Responsibilities of SEQUOIA. In connection with
collecting Biological Materials, SEQUOIA (either directly or through its
collaborators) shall be responsible for obtaining all necessary agreements,
permits, approvals, and consents from foreign and domestic organizations,
governmental agencies, and other people or entities with legal authority to
control access to an area in which collecting activities are to be conducted,
and representatives or governing bodies of indigenous peoples who traditionally
reside in or use such areas. Upon request from ANADYS, SEQUOIA shall provide
documentation regarding such agreements, permits, and approvals for Biological
Materials provided under this Agreement.

                  2.9.3    Compliance With Other Regulations. In performing
their obligations under this Agreement, the Parties will comply with all
applicable present and future orders, regulations, requirements and laws of any
and all federal, state and local authorities and agencies, including without
limitation laws and regulations applicable to the transportation, storage, use,
handling and disposal of hazardous materials.

                                3. LICENSE GRANT

         3.1      License Grant. SEQUOIA hereby grants to ANADYS during the term
of this Agreement, a non-transferable, non-sublicensable, nonexclusive,
royalty-free license under SEQUOIA Proprietary Rights to screen the Samples.
Nothing contained within this Section 3.1 shall be deemed to grant any rights or
other interests in favor of ANADYS with respect to any Patents, trade secrets,
know-how or any other proprietary rights of SEQUOIA discovered, developed or
acquired other than as expressly set forth in this Agreement.

         3.2      Rights to Use and Test Samples. As part of the foregoing
license, ANADYS has the right to use the Samples in any lawful manner in assays,
testing, research, and development. ANADYS shall have complete discretion in all
technical matters. If requested, SEQUOIA shall assist ANADYS in such efforts.

         3.3      Limited Use and Confirmation by a Third Party. ANADYS agrees
and acknowledges that the Samples are provided to ANADYS for purposes consistent
with this Agreement and that any other use of the Samples will be a material
breach of this Agreement Notwithstanding the foregoing, ANADYS shall have the
right to use the data derived from screening the Samples freely, without
limitation or restrictions, for any purpose; provided that ANADYS shall not
publicly disclose chemical structural information of Active Compounds in

                                       9
<PAGE>

such a way that would undermine SEQUOIA'S rights under Section 7.4 of this
Agreement. Consistent with SEQUOIA's obligations to its collaborators, ANADYS
agrees not to transfer Biological Material or Samples provided to ANADYS by
SEQUOIA to a third party without the prior written consent of SEQUOIA. ANADYS
may, however, send Active Samples or Active Compounds to a third party for
screening a particular assay to confirm prior results obtained by ANADYS or to
confirm the chemical structure determined by SEQUOIA. ANADYS shall ensure that
it retains all rights associated with the Active Compounds or Analogs, with
respect to the third party and will report the identity of the third party to
SEQUOIA within ten (10) business days of the transfer of the material to the
third party, unless the Active Compound is subject to an Access Election by
ANADYS, in which case no such notice to SEQUOIA shall be required. Once ANADYS
has made an Access Election with respect to an Active Compound, ANADYS is under
no obligation to report the occurrence of such transfer or the identity of any
third party transferee to SEQUOIA. This Section 3.3 is not intended to limit in
any way activities which ANADYS deems necessary for the development or
commercialization of any Active Compound or Analog, as is contemplated under
this Agreement.

                4. DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS

         4.1      Development of Active Compounds or Analogs. ANADYS shall be
solely responsible and shall have sole discretion for evaluating the potential
for development and commercialization of all Active Compounds or Analogs. In
addition, ANADYS has the right to sublicense Active Compounds. ANADYS, its
Affiliates or sublicensee, or its subcontractor shall be responsible for
conducting all development and evaluations of any Active Compound or Analog and
for filing and obtaining government approval of any such Product(s).

                               5. RESEARCH FUNDING

         5.1      Pilot Study Within [...***...] ([...***...]) business days
following the Effective Date, ANADYS will pay SEQUOIA [...***...] Dollars
($[...***...]) to fund the Pilot Study.

         5.2      Phase 2. In the event that Phase 2 is triggered, ANADYS will
provide research support for [...***...] ([...***...]) FTEs at SEQUOIA for
twelve (12) months. The FTEs will work on research described in Sections 2.2.1,
2.2.2, 2.3.1, 2.3.2, 2.5 and 2.6.2. The funding rate will be $[...***...] per
FTE per year. Any additional research requested by ANADYS during or after the
first twelve months will also be funded at the rate of $[...***...] per FTE per
year; provided, however, that if the twelve (12) month work period is extended
to eighteen (18) months pursuant to either Section 2.2.2 or Section 2.3.1, such
extension alone shall not be deemed a request for additional research and no
additional research funding payments will be required by virtue of such
extension.

         5.3      Access Election Fees. Pursuant to Section 2.4.1, ANADYS will
pay SEQUOIA $[...***...] for each Access Election for each of the first ten (10)
Active Compounds elected pursuant to Section 2.4 and $[...***...] for each
Active Compound so elected thereafter. For all Access Elections that occur
during 2002 or 2003, these payments will accumulate until January 1, 2004 and be
due on February 1, 2004. For Access Elections that occur after January 1, 2004,

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       10
<PAGE>

these payments will be made by ANADYS to SEQUOIA within thirty (30) days from
the date of the Access Election as described in Section 2.4.1.

         5.4      Payments for Milestones Achieved by ANADYS. ANADYS shall pay
SEQUOIA non-refundable, non-creditable, one-time-only milestone payments in the
amounts indicated in Table 1 upon the occurrence of the Milestones set forth in
Table 1 with respect to any Active Compound or Analog that is developed by
ANADYS, its Affiliates or sublicensees. Each milestone payment shall be payable
only upon the first occurrence of each Milestone with respect to any Active
Compound or Analog thereof.

Table 1. Milestones and Milestone Payments

<TABLE>
<CAPTION>
           Milestone                           Payment to Sequoia
-------------------------------                ------------------
<S>                                            <C>
In vivo efficacy demonstration                    $[...***...]
IND Filing                                        $[...***...]
Initiation of Phase III studies                   $[...***...]
First Marketing Approval                          $[...***...]
</TABLE>

         5.5      Royalties. ANADYS shall pay to SEQUOIA a [...***...] percent
([...***...]%) royalty on Net Sales of Product(s). ANADYS's obligation to pay
royalties shall begin on the date of the first commercial sale of Product in any
country, and shall end upon (a) the date valid, unexpired claims covering such
Product in that country have expired, or (b) [...***...] ([...***...]) years
from the date of the first arms-length commercial sale of product in that
country, whichever is earlier.

                          6. TERMS OF RESEARCH FUNDING

         6.1      Research Fees. Within ten (10) business days of the Effective
Date, ANADYS will pay SEQUOIA the research fee described in Section 5.1. If
Phase 2 is commenced, ANADYS will pay SEQUOIA a total of $[...***...] payable as
follows: The first $[...***...] will be due within ten (10) days after the Phase
2 Commencement Date, but not prior to January 1, 2003 and the second
$[...***...] will be due ninety (90) days after the first $[...***...] payment.
The first Phase 2 payment of $[...***...] will be received by SEQUOIA prior to
shipment of the [...***...] additional Samples to ANADYS. Payments by ANADYS
will be due thirty (30) days from the date of invoice. Invoices will be sent to
Chief Financial Officer, Anadys Pharmaceuticals, 9050 Camino Santa Fe, San
Diego, CA 92121. All payments shall be in US dollars.

         6.2      Milestone Payments. Upon the occurrence of any of the
milestones listed in Section 5.4, Table 1, ANADYS will notify SEQUOIA in writing
within thirty (30) days of completion of each milestone. ANADYS will pay to
SEQUOIA the milestone payments as set forth in Section 5.4, Table 1, within
sixty (60) days of such notice. All payments shall be in US dollars.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       11
<PAGE>

         6.3      Royalty Payments by ANADYS. Royalties shall be calculated semi
annually as of June 30 and December 31 (each being the last day of an
"Accounting Period') and shall be payable on a semi-annual basis within ninety
(90) days after the end of each Accounting Period in which such Net Sales occur.
"Accounting Period" means a calendar half commencing respectively on January 1
and July 1, each being the first day of an Accounting Period, and finishing
respectively on June 30 and December 31, each being the last day of an
Accounting Period. All payments shall be in US dollars.

         6.4      Royalty Reports. ANADYS shall furnish to SEQUOIA at the time
each royalty payment is made, a written report of the Net Sales of the
Product(s) and the royalty due and payable, on a country-by-country basis, for
the Accounting Period upon which the royalty payment is based. Royalty reports
shall contain the following information: gross sales of Product(s) in each
country of sale, with adjustments and calculation of Net Sales in the currency
of sale, and conversion into U.S. dollars, together with the exchange rates used
for conversion. SEQUOIA shall maintain all such reports in confidence. The
buying rates involved for the currency of the United States into which the
currencies involved are being exchanged shall be the one quoted by The Wall
Street Journal at the close of business on the last business day of the relevant
Accounting Period. Such amounts shall be paid without deduction, except as
required by law, of any withholding taxes, value-added taxes, or other charges
applicable to such payments

         6.5      Inspection of Books and Records. ANADYS shall maintain
accurate books and records that enable the calculation of milestone payments and
royalties payable hereunder to be verified. ANADYS shall retain the books and
records for each Accounting Period for two (2) years after the submission of the
corresponding reports or notifications under Section 6.4. Upon the written
request of SEQUOIA, at least thirty (30) days in advance, and not more than once
in each calendar year, ANADYS will permit SEQUOIA's independent certified public
accountant to have access during normal business hours to such of the records of
ANADYS as may be reasonably necessary to verify the accuracy of the reports
submitted to SEQUOIA hereunder for the 12 months preceding the date of such
request. SEQUOIA shall not be entitled to inspect or audit the same records more
than once. The accounting firm shall report to SEQUOIA only whether there has
been an underpayment and, if so, the amount thereof. No other information will
be provided to SEQUOIA. The foregoing access shall be permitted during the term
of this Agreement and after the expiration or termination of this Agreement,
provided milestone or royalty obligations hereunder are still in effect. Any
such inspection or audit shall be at SEQUOIA's expense. SEQUOIA will treat all
financial information subject to review under this Section 6.5 in accordance
with the confidentiality provisions of Section 8 and will cause its accounting
firm to enter into an acceptable confidentiality agreement with ANADYS
obligating such firm to retain all such financial information in confidence
pursuant to such confidentiality agreement.

         6.6      Benefit Sharing. SEQUOIA has entered into contracts requiring
SEQUOIA to pay portions of the payments that it may receive pursuant to Sections
5.1, 5.2, 5.3 5.4 and 5.5 to certain of its collaborators as access fees and to
promote conservation of biological diversity. Such payments shall be the sole
responsibility of SEQUOIA.

                                       12
<PAGE>

                7. OWNERSHIP OF MATERIALS, INTELLECTUAL PROPERTY

         7.1      Sole and Joint Inventions. All inventions made solely by
employees or agents of a single Party in the course of performing work under
this Agreement ("Sole Inventions") shall be owned solely by that Party. All
Inventions jointly made by employees or agents of both Parties in the course of
performing work under this Agreement ("Joint Inventions") shall be owned solely
by ANADYS and shall be assigned to ANADYS, consistent with the terms of Sections
2.4, 2.7, and 5.3 and of this Agreement. In addition, all intellectual property
generated by employees or agents of SEQUOIA that is based on or derived from
ANADYS Proprietary Rights shall be assigned to ANADYS.

         7.2      Patent Costs and Filing Fees. Any Party who is the owner of a
Sole Invention shall have the right to prepare, file, prosecute, and maintain
patent applications and patents throughout the world in countries of its choice
regarding the invention, at its own expense. With respect to Joint Inventions,
ANADYS shall diligently prepare, file, prosecute, and maintain the patents in
its sole discretion and at its sole expense. In the event that SEQUOIA does not
file, prosecute or maintain patent applications for its Sole Inventions, or
decides to abandon prosecution of a filed application for any of its Sole
Inventions, then ANADYS shall have the right, but not the obligation, to file,
prosecute and/or maintain such patent(s) in its own name and at its own expense,
and SEQUOIA shall assign to ANADYS the rights to such Sole Invention.

         7.3      Cooperation in Filing. The Parties agree to cooperate with
each other in preserving and perfecting each other's intellectual property
rights that arise in the course of work under this Agreement or arising out of
this Agreement, and in particular agree that their personnel shall sign
documents as and when provided to comply with patent laws and regulations,
including inventor declarations and assignments of ownership worldwide.

         7.4      ANADYS Elects Not to File Patent. In the event ANADYS, its
Affiliates or its sublicensees elecs not to file or continue to prosecute an
application for a patent on a Joint Invention, or to abandon an issued patent on
a Joint Invention in any country, ANADYS shall notify SEQUOIA, and thereafter
SEQUOIA, at its expense and in its sole discretion, shall have the right to file
a patent on such Joint Invention or to pursue prosecution of such patent
application or maintenance of such issued patent. ANADYS shall assist SEQUOIA at
SEQUOIA's expense in filing, obtaining and maintaining such patents (including
assigning or licensing such inventions or Patents to SEQUOIA). All such Patents
that are obtained by SEQUOIA at its expense under this Section 7.4 shall be
assigned to SEQUOIA. Such assignment shall take place in a timely manner to meet
any external requirement concerning prosecution matters and paying prosecution
and maintenance costs.

         7.5      Data and Information. Each Party shall own all data and
information created by the Party. Notwithstanding the foregoing, should SEQUOIA
assign an invention to ANADYS pursuant to Section 7.1, ownership of all data and
information associated with the invention shall also be assigned over to ANADYS.

                                       13
<PAGE>

                               8. CONFIDENTIALITY

         8.1      Confidential Information. The Parties agree to treat as
confidential any and all Confidential Information obtained from each other. The
material terms of this Agreement shall also be considered confidential.
Notwithstanding the foregoing, Confidential Information may be disclosed to the
extent required by any law or regulation of any governmental authority having
jurisdiction over any of the Parties, with appropriate efforts made to maintain
confidentiality.

         8.2      Maintaining Confidential Information. Both Parties shall
maintain Confidential Information in confidence as set forth herein, for a
period of [...***...] ([...***...]) years beyond termination or expiration of
this Agreement. Upon request from either Party, the confidentiality of specific
Confidential Information may be maintained for a longer time, as the Parties may
subsequently agree in writing. The foregoing obligations will not apply to
information that the receiving Party can establish by written records: (a) was
known by the receiving Party prior to the receipt of the Confidential
Information; (b) was disclosed to the receiving Party by a third party having
the right to do so; (c) was, or subsequently became, in the public domain
through no fault of the receiving Party, its officers, directors, employees or
agents; (d) was independently developed by the receiving Party without use of
the Confidential Information; (e) was disclosed with the written consent of the
Party from whom the information was obtained; or (f) was disclosed by the
receiving Party pursuant to any judicial, governmental or stock exchange
request, requirement or order, so long as the receiving Party provides the
disclosing Party with sufficient prior notice to contest such request,
requirement or order.

         8.3      Scientific Publications. Subject to the confidentiality
provisions set forth herein, the Parties agree to cooperate in making the
results of research conducted under this Agreement available for publication.
Prior to submission for publication of any manuscript relating to the research
described herein, SEQUOIA and ANADYS shall provide each other with a copy at
least thirty (30) days prior to any scheduled publication or presentation date.
Upon request, publication will be delayed for up to sixty (60) days from the
date of notification by the other Party to allow a patent application to be
filed. In lieu of a delay, the information identified as Confidential
Information belonging to a Party shall be deleted. It is contemplated that
SEQUOIA and its collaborators will be recognized as co-authors on any scientific
publications that are produced or otherwise as appropriate, consistent with
professional and legal standards, and in any event to be acknowledged as the
source of the Biological Material and any associated information.

         8.4      Public Release of Information. Except as set forth in this
section, neither Party may use or permit others to use the name, trademarks or
Confidential Information of the other Party, without the advance written consent
of that Party. Foreign government agencies that have executed plant collection
agreements with SEQUOIA have requested and SEQUOIA has agreed that they will be
notified of the identity of transferees of Samples hereunder, of agreements such
as this Agreement, and of progress of milestones reached and general fields of
commercial interest for the Samples or compounds therein. ANADYS acknowledges
that nothing herein prohibits SEQUOIA from advising such agencies that ANADYS is
a transferee of Samples hereunder. The Parties shall consult with each other
regarding the form and content of any

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                       14
<PAGE>

public announcements or disclosures and will not make any public announcement or
disclosure without notifying the other Party in advance and receiving their
prior written approval.

                        9. REPRESENTATION AND WARRANTIES

         9.1      Representations and Warranties. Each Party represents and
warrants that (i) it has all necessary right and authority to enter into and
perform this Agreement; (ii) it has obtained or will obtain all consents,
licenses or other permits needed by it to perform this Agreement and it will
comply with all applicable laws; (iii) it has sufficient legal and/or beneficial
title under its intellectual property rights necessary to perform activities
contemplated by this Agreement and to grant the licenses and assignments
contained in this Agreement; and (iv) it is not under any duty to, and has not
entered into an agreement with, any third party that is in conflict with this
Agreement. SEQUOIA further covenants to ANADYS that any payments or obligations
that it has owing at any time to any third party shall be made or fulfilled in a
manner so as not to adversely affect, directly or indirectly, any of ANADYS'
rights under this Agreement.

         9.2      Limitations. Biological Material, Samples and other material
delivered pursuant to this Agreement are understood to be experimental in nature
and may have hazardous properties requiring the receiving Party to take
appropriate precautions to minimize any health risk. NEITHER PARTY MAKES ANY
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR
IMPLIED, EXCEPT AS SET FORTH ABOVE. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES
OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE
MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER
PROPRIETARY RIGHTS.

         9.3      Employee Proprietary Information and Inventions Agreement.
Each Party represents and warrants that each employee of that Party, as a
condition of employment, is required to execute and deliver an employee
proprietary information and inventions agreement, which assigns all inventions
conceived by such officer or employee to that Party.

                               10. INDEMNIFICATION

         10.1     ANADYS Indemnity. ANADYS shall indemnify and hold SEQUOIA, its
officers, directors, shareholders, owners, employees, and agents ("SEQUOIA
Indemnitees") harmless from all suits, claims, demands, judgments, liabilities,
costs, charges, or expenses (including reasonable attorney's fees) (collectively
"Losses") to which the SEQUOIA Indemnitee may become subject as a result of any
claim, demand, action or other proceeding by any third party to the extent that
such Losses result from ANADYS's development, manufacture, use, or sale of any
Biological Material, Samples, Active Samples, Active Compounds, Analogs, or
Products, except those resulting from any production, manufacture, or use of the
Biological Material, Samples, Active Samples, Active Compounds, Analogs and/or
Products by SEQUOIA pursuant to this Agreement or the gross negligence or
willful misconduct (whether by act or omission) on the part of SEQUOIA or its
collaborators.

                                       15
<PAGE>

         10.2     SEQUOIA Indemnity. SEQUOIA shall indemnify and hold ANADYS,
its officers, directors, shareholders, owners, employees, and agents ("ANADYS
Indemnitees") harmless from all Losses to which the Anadys Indemnitee may become
subject which result from (i) any production, manufacture, or use of the
Biological Material, Samples, Active Samples, Analogs, Active Compounds and/or
Products by SEQUOIA pursuant to this Agreement; (ii) the gross negligence or
willful misconduct (whether by act or omission) on the part of SEQUOIA or
collaborators; and (iii) the breach by SEQUOIA of any of its representations,
warranties or covenants set forth in Section 9 of this Agreement.

                            11. TERM AND TERMINATION

         11.1     Term. This Agreement has an initial term of two (2) years from
the Effective Date.

         11.2     Survival. The obligations and rights contained in Sections
2.2.4, 2.4.1, 2.4.2, 2.5, 2.7, 4, 5, 6, 7, 8, 9, 10, 11.2, 11.3, 11.5, 12 and 13
shall survive the expiration or other termination of this Agreement.

         11.3     Return of Materials. Upon termination or expiration of this
Agreement, each Party shall promptly return to the other Party all Confidential
Information received from the other Party (except one copy of which may be
retained for archival purposes).

         11.4     Permissive Termination. In the event that either Party shall
be in default of any obligation hereunder, either Party shall have the right to
terminate this Agreement by giving thirty (30) days written notice to the
defaulting Party, specifying the basis for termination. If, within such thirty
(30) day period, the Party who received notice takes steps necessary to remedy
the default, such notice shall cease to be operative, and this Agreement shall
continue in full force. The waiver of a breach hereunder may be effected only by
a writing signed by the waiving Party and shall not constitute a waiver of any
other breach. Notwithstanding the foregoing, if ANADYS has not made an Access
Election on an Active Compound pursuant to the provisions of Section 2.4.1 prior
to termination as per this Section 11.4, SEQUOIA, in its sole discretion, may
elect to file a patent on any such Active Compound pursuant to the provisions of
Section 7.4. In the event of any liquidation, dissolution or winding up of
SEQUOIA, either voluntary or involuntary, ANADYS shall have the right to
terminate this Agreement immediately. In the event of an Anadys Corporate Event,
ANADYS shall have the right to terminate this Agreement upon ten (10) days
written notice to SEQUOIA, which notice may be provided prior to, but contingent
on, the consummation of such ANADYS Corporate Event.

         11.5     Bankruptcy Rights. In the event that this Agreement is
terminated or rejected by a Party or its receiver or trustee under applicable
bankruptcy laws due to such Party's bankruptcy, and if this Agreement is not
earlier terminated pursuant to Section 11.4 above, then all rights and licenses
granted under or pursuant to this Agreement by such Party to the other Party
are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the
Bankruptcy Code and any similar law or regulation in any other country, licenses
of rights to "INTELLECTUAL PROPERTY" as defined under Section 101(52) of the
Bankruptcy Code. The Parties agree that all intellectual

                                       16
<PAGE>

property rights licensed hereunder, including without limitation any patents or
patent applications in any country of a Party covered by the license grants
under this Agreement, are part of the "INTELLECTUAL PROPERTY" as defined under
Section 101(52) of the Bankruptcy Code subject to the protections afforded the
non-terminating Party under Section 365(n) of the Bankruptcy Code, and any
similar law or regulation in any other country.

                             12. DISPUTE RESOLUTION

         12.1     Resolution. If ANADYS and SEQUOIA, are unable to resolve any
dispute between them, either ANADYS or SEQUOIA may, by written notice to the
other, have such dispute referred to the CSO of ANADYS and SEQUOIA (or their
designees or equivalents), for attempted resolution by good faith negotiations
within twenty-one (21) days after such notice is received. If the Parties are
unable to resolve such dispute within such twenty-one (21) day period, either
Party shall have the right to pursue any and all other remedies available to
such Party.

                          13. MISCELLANEOUS PROVISIONS

         13.1     Governing Law. This Agreement shall be governed by the laws of
the state of California, without reference to any rules of conflict of laws.

         13.2     Independent Contractors. The relationship of the Parties
established by this Agreement is that of independent contractors. Nothing in
this Agreement shall be construed to create any other relationship between the
Parties. Neither Party shall have any right, power or authority to assume,
create or incur any expense, liability or obligation, express or implied, on
behalf of the other.

         13.3     Severability. If any term or provision of this Agreement is or
becomes invalid or held illegal or unenforceable by a court of competent
jurisdiction, then (i) it is the intention of the Parties that the remaining
terms or provisions of this Agreement shall not be affected thereby and shall be
enforced to the fullest extent permitted by law, and (ii) the Parties shall
renegotiate in good faith such invalid, illegal or unenforceable term or
provision in order to provide a reasonably acceptable alternative whose effect
on economic and business objectives shall be as similar as possible to the
effect intended by the Parties under the original invalid, illegal or
unenforceable term or provision, it being the intent of the Parties that the
basic purposes of this Agreement are to be effectuated.

         13.4     Notices. All written communications and notices between the
Parties under this Agreement shall be deemed given when delivered in person, or
when received by mail, postage prepaid, registered or certified mail, express
courier, or facsimile, to the addresses below, and with proof of delivery
received by the sender.

                  ANADYS:  VP, Corporate Development
                           9050 Camino Santa Fe
                           San Diego, CA 92121
                           USA

                                       17
<PAGE>

                  SEQUOIA: President & CEO
                           11199 Sorrento Valley Road, Suite H
                           San Diego, CA 92121
                           USA

or any other addresses of which either Party shall notify the other Party in
writing.

         13.5     Force Majeure. Neither Party will be liable for its failure to
perform any of its obligations hereunder during any period in which such
performance is delayed by acts of God, fire, ware, embargo, riots, strikes or
other similar cause outside the control of such Party; provided, however, that
in the event that such event of Force Majeure delays the performance of either
Party for a period in excess of ninety (90) days, the other Party shall have the
right to terminate this Agreement upon written notice.

         13.6     Assignment. Neither Party may assign or otherwise transfer
this Agreement or any of its rights or obligations hereunder without the prior
written consent of the other Party, which consent shall not be unreasonably
withheld.

         13.7     Waiver. A failure of either Party to exercise any right or
remedy hereunder, in whole or in part, or on one or more occasions, will not be
deemed either a waiver of such right or remedy to the extent not exercised, or
of any other right or remedy, on such occasion or a waiver of any right or
remedy on any succeeding occasion. No waiver of any default, condition,
provisions or breach of this Agreement will be deemed to constitute a waiver of
any other default, condition, provision or breach of this Agreement. A waiver of
any default, condition, provision or breach of this Agreement will be in writing
duly signed by an authorized representative of the Party waiving such default,
condition provision or breach.

         13.8     Amendment. No amendment, modification or supplement to this
Agreement or any exhibit hereto or any of their provisions will be binding upon
either Party unless made in writing and duly signed by an authorized
representative of both SEQUOIA and ANADYS. In no event may the terms of this
Agreement be changed, deleted, supplemented or waived by any notice, purchase
order, receipt, acceptance, bill of lading or other similar form of document.

         13.9     Entire Agreement. This Agreement sets forth the entire
understanding and agreement of the Parties as to the subject matter hereof, and
supersedes and terminates all prior agreements and understandings between
Parties with respect to the subject matter hereof. There are no other
understandings, representations or promises, written or verbal, not set forth
herein or on which either Party has relied.

         13.10    Limitation of Liability. NEITHER PARTY WILL BE LIABLE TO THE
OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT OR PUNITIVE
DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF
LIABILITY.

                                       18
<PAGE>

         13.11    Headings. headings included herein are for convenience only,
do not form a part of this agreement and shall not be used in any way to
construe or interpret this Agreement.

         13.12    Construction. This Agreement will be construed without regard
to the drafting or non-drafting Party hereto.

         13.13    Counterparts. This Agreement may be executed in two or more
counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument. Counterparts may be signed
and delivered by facsimile, each of which will be binding when sent, and in each
case an original will be sent via overnight courier.

         IN WITNESS WHEREOF, the ANADYS and SEQUOIA have caused this Agreement
to be executed by their duly authorized representatives effective on the later
date stated below:

SEQUOIA SCIENCES, INC.                          ANADYS PHARMACEUTICALS, INC.

By:    /s/ Gary Eldridge                        By:    /s/ Michael J. Kamdar
       ----------------------                          -------------------------
       Gary Eldridge                                   Michael J. Kamdar
Title: President and CEO                        Title: Vice President, Corporate
                                                       Development and Strategy

Date:  10 Oct 02                                Date:  October 10, 2002

                                       19<PAGE>

                                                                   EXHIBIT 10.20

         *** CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT
         (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
         SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR
         CONFIDENTIAL TREATMENT UNDER 17 C.F.R. SECTIONS 200.80(B)(4), 200.83
         AND 230.406.

                                                                    Page 1 of 13

                          TECHNOLOGY LICENSE AGREEMENT

                                     between

               EMBL Enterprise Management Technology Transfer GmbH
                                 Boxbergring 107
                                69126 Heidelberg

                      represented by the Managing Director
                              - hereafter EMBLEM -

                                       and

                           ANADYS PHARMACEUTICALS, INC
                                    Delaware

                      represented by the Managing Director
                              - hereafter ANADYS -

                                    PREAMBLE

ANADYS desires to employ proprietary technologies developed at the European
Molecular Biology Laboratory (EMBL) -represented by EMBLEM in accordance with
the Master License Agreement between EMBL and EMBLEM from December 10, 1999- to
identify, characterize and functionally analyze RNA-containing subcellular
complexes and assemblies sourced from normal and / or pathological tissues of
all species. ANADYS intends to utilize this information to identify drug targets
used or useful in the discovery or development of drugs, diagnostics or
vaccines.

The EMBL technology platforms that ANADYS seeks to utilize include, but are not
limited to, mass spectrometry, computational biology, retrieval and purification
of RNA-protein complexes, genetic screens, microscopy, biological and
biochemical assays, in vivo RNA assays, genomics and virology. The access of
ANADYS to these technology platforms will be limited to applications in ANADYS's
field of research.

ANADYS will pursue programs with respect to any human disease, including without
limitation, infectious diseases, proliferative diseases, and diseases of the
cardiovascular and central nervous system.

<PAGE>

ANADYS TECHNOLOGY LICENSE AGREEMENT

                                                                    Page 2 of 13

                                    ARTICLE 1
                                   DEFINITIONS

For the purpose of this contract the following definitions apply.

(1)      "Field" means ANADYS's field of research and development specified as
follows: ANADYS's field includes proprietary and non-proprietary substances,
components, techniques and methods in the area of RNA biology, including
posttranscriptional gene expression and its regulation. The Field includes
substances, compounds and molecular components derived from normal, infected,
pathological or engineered cells of all species, for use and application to any
human disease, excluding diseases related to metal metabolism.

(2)      "Licensed Patents" means the patents and patent applications of
EMBL/EMBLEM, that are listed in ANNEX 1 including reissues, continuations,
continuations-in-part, divisions, extensions and reexaminations thereof, and the
patents and patent applications that the parties shall subsequently include in
ANNEX 1 by mutual agreement.

(3)      "Licensed Technology" means the Licensed Patents and methods, results,
data, substances, processes, compositions of matter, biological and other
material, formulas, know-how, inventions and information developed by EMBL in
the Field, whether tangible or intangible, whether or not utilizing Licensed
Patents, that are listed in ANNEX 2 and that the parties shall subsequently
include in ANNEX 2 by mutual agreement.

(4)      "Founders" are the following scientists at EMBL:

-        Iain Mattaj

-        Matthias Hentze

The term "Founder" in this agreement does in no way prejudice the distribution
of equity or the personal involvement of these persons or of other persons in
ANADYS.

(5)      "Research groups of Founders" means all members of personnel who are
employed or hold fellowships at EMBL for research purposes and who are assigned
to the respective Founder as Group Leader.

(6)      "Intellectual Property" means the following, in the Field:

         (i)      inventions, patents, patent applications and statutory
                  invention registrations, including reissues, continuations,
                  continuations-in-part, divisions, extensions and
                  reexaminations thereof, and

         (ii)     confidential and proprietary information, including trade
                  secrets and know-how, methods, results, data, substances,
                  processes, compositions of matter, biological and other
                  material, and formulas.

<PAGE>

ANADYS TECHNOLOGY LICENSE AGREEMENT

                                                                    Page 3 of 13

                                    ARTICLE 2
                                     LICENSE

(1)      EMBLEM grants ANADYS an exclusive royalty free worldwide license to the
Licensed Technology and to make, use, sell and offer to sell products, methods
and processes claimed in the Licensed Patents with the right to sublicense.
ANADYS grants to EMBLEM a non-exclusive, royalty-free sublicense to use the
Licensed Technology and to make and use products, methods and processes claimed
in the Licensed Patents for EMBL academic research. EMBLEM shall have no right
to further sub-license these rights except that EMBLEM/EMBL may make available
to academic researchers, under appropriate material transfer agreements (forms
of which will be made available to ANADYS) non-transferable non-exclusive
licenses for their own non-commercial research. EMBLEM will provide ANADYS with
a quarterly list of those institutions that have been granted rights to use the
Licensed Patents and the Licensed Technology.

(2)      During a period of four years after May 19, 2000 and subject to
existing commitments to others, EMBLEM shall provide to ANADYS in writing under
confidentiality according to article 7 of this agreement, a summary notification
about any Intellectual Property concerning methods or techniques in the Field
developed by or held by EMBLEM and not covered by Article 2, Paragraph (3), when
such Intellectual Property becomes available for licensing. No field medical use
and no composition are included in the scope of this provision. Such
notification shall be non-exclusive and shall not constitute a license. Any
subsequently negotiated license to ANADYS shall be at fair market value.

(3)      EMBLEM shall provide ANADYS exclusive written information for
Intellectual Property in the Field developed in the EMBL groups of the Founders
within a period of four years after May 19, 2000. ANADYS shall notify EMBL
within thirty days after having received this written information about the
patents or technologies if it wishes to accept the license. If ANADYS wishes to
accept the license, EMBLEM and ANADYS agree that this Intellectual Property will
be added to ANNEX 1 as Licensed Patents or Licensed Technology in accordance
with the terms of this agreement. In the absence of a request by ANADYS to
license the Intellectual Property, EMBL is free to publish, utilize or license
the Intellectual Property at its discretion and to other parties. In the case of
Intellectual Property which is not yet patented or otherwise protected, ANADYS
shall also notify EMBLEM in writing within thirty days if EMBL must seek patent
protection for the technology at ANADYS's expense, and exclusively under
ANADYS's control. If no such notification is given, EMBL/EMBLEM is free to
patent the technology at its own expense. In any case, preparation of patent
protection must not require delay in submission for relevant publication for
more than 60 days from the original notification by EMBLEM/EMBL.

(4)      ANADYS Inc shall maintain considerable facilities for the exploitation
and, the use of the licensed technology in Europe.

(5)      ANADYS shall impose the limitations of the licenses granted under this
agreement to it's sub-licensees.

<PAGE>

                                                                    Page 4 of 13

                                    ARTICLE 3
                              INTELLECTUAL PROPERTY

(1)      All Intellectual Property, whether protected or not, developed by one
of the parties to this agreement shall belong to the party of the inventor(s).
Discoveries made jointly by inventors from both parties shall become Joint
Intellectual Property. For such Joint Intellectual Property, the parties will
agree on the share of each party. During the term of this agreement, ANADYS will
control, and will assume the costs of, filing, prosecuting, and maintaining
patent applications on Joint Intellectual Property. During the terms of this
agreement, ANADYS will assume the costs of, as well as retain any damages
recovered in an action for infringement or misappropriation of Joint
Intellectual Property. If it becomes necessary for EMBLFM to join as a party to
an action to protect the Joint Intellectual Property, EMBLFM agrees to join such
an action, with its reasonable costs to be borne by ANADYS.

(2)      If ANADYS does not wish to protect a certain piece of Joint
Intellectual Property or no longer wishes to maintain the protection, ANADYS
shall inform EMBLEM. EMBLEM is then free to protect or maintain protection to
this piece of Joint Intellectual Property at its own costs.

(3)      For a period of four years from May 19, 2000 Joint Intellectual
Property developed jointly by ANADYS and the groups of the Founders shall be
treated as Licensed Technology or Licensed Patents under this agreement (see
Article 2). For Intellectual Property developed jointly by ANADYS and other
groups in EMBL, the parties will negotiate in good faith respective licenses at
fair market value.

(4)      [...***...]

(5)      If and to the extent that ANADYS is made subject of a litigation with
respect to the use of the Licensed Rights or the Licensed Technology on the
basis of violation of a third party's intellectual property rights, ANADYS shall
inform EMBLEM immediately of such litigation. EMBLEM shall be obligated to join
ANADYS as intervening party (als Nebenintervenient beitreten) on demand of
ANADYS and to support ANADYS' defense. ANADYS shall bear the costs of such
intervention unless the infringement is based on gross negligence or willful
intent by EMBLEM.

(6)      If and to the extent that EMBLEM is made subject of a litigation with
respect to a third party's intellectual property rights and if such litigation
could adversely effect ANADYS' right hereunder, EMBLEM is obligated to use its
best efforts as to the defense of its rights and the rights of ANADYS. EMBLEM
shall inform

                                             ***CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                                                    Page 5 of 13

ANADYS immediately of such litigation. ANADYS has the right but not the
obligation to join EMBLEM as intervening party (als Nebenintervenient beitreten)
and support EMBLEM's defense. ANADYS shall bear the costs of such intervention
unless the infringement is based on gross negligence or willful intent by
EMBLEM.

                                    ARTICLE 4
                             COOPERATION AND SUPPORT

(1)      EMBLEM via EMBL shall assist ANADYS with training and support: in
practicing the Licensed Technology. The amount of such training and support
shall be limited to a reasonable level, which will be agreed by the parties in
good faith.

(2)      Within the framework of Technology Transfer Policies at EMBL,
EMBLEM/EMBL agrees that the Founders may consult or otherwise spend part of
their time for ANADYS subject to individual agreements with ANADYS that require
approval of EMBL/EMBLEM.

(3)      EMBLEM shall also assist ANADYS with respect to filing, prosecuting,
and maintaining the Licensed Patents.

                                    ARTICLE 5
                                  CONSIDERATION

(1)       As consideration in full for the grant of the license under this
agreement, ANADYS shall grant: to i) EMBL, or its designee, EMBLEM Technology
Transfer GmbH and ii) certain other participating individuals as listed on ANNEX
3, a total of 2,090,335 shares of restricted Common Stock of ANADYS
Pharmaceuticals, Inc. representing approximately 9.20% of the share capital. The
grant to EMBLEM includes without limitation, all shares of restricted Common
Stock of ANADYS, Inc. which ANADYS has designated for the Founders and which
EMBLEM will assign to EMBL and EMBL to the Founders by mutual agreement between
EMBL and the Founders following the entry into force of this Agreement. ANADYS
will deliver the shares to the EMBLEM and the other individuals within 30 days
following receipt of the payment of the nominal cost of the shares.

(2)      For any license granted to ANADYS according to Article 2, Paragraph
(3), ANADYS shall pay a sum to be negotiated in good faith between the parties
to EMBLEM within sixty days after notifying EMBLEM of its acceptance of such
license, or within sixty days after a royalty is negotiated, whichever is later.
If the parties do not agree a fair value, the payment shall be set at EUROs
25.000 per license.

(3)      ANADYS will not broker Licensed Rights and Licensed Technology by
sublicensing to third parties without adding significant value. In case ANADYS
sublicenses part or all of the Licensed Rights or Licensed Technology without
adding additional value to it, ANADYS shall pay appropriate compensation to
EMBL.

<PAGE>

                                                                    Page 6 of 13

(4)      EMBLEM shall have the right to access ANADYS' books and accounting upon
request limited to information relating to royalty payments on sublicenses.

                                    ARTICLE 6
                            WARRANTIES AND LIABILITY

(1)      EMBLEM assures that it is not aware of any third party rights
conflicting with the rights granted to ANADYS by EMBLEM. EMBLEM further assures
that, to the best of its knowledge, that the issued Licensed Patents are valid
and enforceable. Beyond the warranties given under this section EMBLEM shall not
assume any liability for the protectability of the rights granted.

(2)      In the event that the documents furnished by EMBLEM (drawings,
descriptions, etc.) are faulty, inconsistent, incomplete or otherwise impaired,
EMBL shall supply to ANADYS revised copies without delay. EMBLEM shall be liable
for faulty documents prepared by EMBLEM only if supplied intentionally or by
gross negligence.

(3)      EMBLEM shall not assume any responsibility for the commercial
exploitability of the Licensed Patents or Licensed Technology.

(4)      EMBLEM shall not be liable for damages caused by products manufactured
in exploitation of the Licensed Patents or Licensed Technology. The observance
of any provisions, rules and regulations of the law shall be the responsibility
of ANADYS. In particular ANADYS shall be responsible for the observance of
regulations on quality assurance, product safety, and the assumption of product
liability. This shall also apply if EMBLEM/EMBL provides advice, instructions or
training to ANADYS or its staff.

(5)      If EMBLEM makes available to ANADYS any equipment or devices this shall
only be considered as a service rendered as a favor and shall not establish any
rights of ANADYS, in. particular for warranties or damage compensation.

(6)      ANADYS shall ensure that EMBLEM is exempted from any claims that may be
raised against EMBLEM either as manufacturer or as quasi-manufacturer of the
products produced by .ANADYS.

(7)      EMBLEM shall be held liable on whichever legal grounds only for damages
caused by intent or gross negligence. Such liability shall not exceed EURO
1,000,000. If this limitation is invalid in certain cases, the liability of EMBL
shall be restricted to an amount foreseeable at the time of conclusion of this
contract.

                                    ARTICLE 7
                        CONFIDENTIALITY AND PUBLICATIONS

(1)      Each party may mark any written information confidential.

<PAGE>

ANADYS TECHNOLOGY LICENSE AGREEMENT

                                                                    Page 7 of 13

(2)      The parties agree that confidentiality is essential for the realization
and discharge of this contract. Therefore, they both incur the firm commitment
to develop and conclude a fairly negotiated agreement on confidentiality and
publications within 30 days after the date hereof. This agreement shall enable
both parties to mark information confidential and shall also stipulate the
general extent and duration of confidentiality obligations of either party.

(3)      During the term of this agreement and for a period of three years after
termination of the agreement the parties agree to utilize any secrets or any
know-how gained during their relationship from other party exclusively to the
extent stipulated in this agreement. They shall not disclose or make available
such information to third parties

(4)      This obligation shall not extend to any information which.

         (a)      is already known to the receiving party,

         (b)      is or becomes in the public domain without breach of the
                  confidentiality provisions by the receiving party,

         (c)      Is received by the receiving party from a third party not
                  under an obligation of confidentiality to the other party,

         (d)      Is independently developed by the receiving party without use
                  of the confidential information of the disclosing party.

The obligation shall also not apply to the extent that disclosure is required by
law.

(5)      The parties shall extend this obligation to their employees and to
third party companies as may be involved.

(6)      Each party has the right to review any materials or publications using
this party's name prior to publication.

                                    ARTICLE 8
                                      TAXES

Taxes that are due on license fees are borne by ANADYS. ANADYS has the right to
deduct certain taxes from the license fee payments due, provided that

-    EMBLEM is entitled for reimbursement of those taxes and

-    that ANADYS delivers immediately to EMBLEM all tax certificates or other
     evidence in a format that is acceptable to the tax authorities responsible
     for the reimbursement.

<PAGE>

ANADYS TECHNOLOGY LICENSE AGREEMENT

                                                                    Page 8 of 13

                                    ARTICLE 9
                               GENERAL PROVISIONS

(1)      This agreement was done in two originals. Each party has received one
original.

(2)      No oral alterations or amendments to this agreement have been made. Any
alterations or amendments shall be made in writing. This provision can only be
waived in writing.

(3)      If any term or provision of this agreement shall be or becomes invalid,
such invalidity shall not affect the validity of the remaining provisions of
this agreement. Gaps in the agreement, invalid terms or provisions shall be
replaced in such a way that comes as closely as possible to the original
intentions of the parties and the economic results of the original provision.

                                   ARTICLE 10
                                  EXPLOITATION

(1)      ANADYS will provide to EMBLEM by October 1 for the following year,
first on October 1, 2000, an annual development plan setting forth reasonable
goals for, as well as ANADYS's progress in, development and exploitation of the
Licensed Technology and Licensed Patents and will endeavor to reach these goals.

(2)      ANADYS will use the Licensed Technology and the Licensed Rights only in
accordance with the applicable laws and regulations.

(3)      In case of bankruptcy of ANADYS receivership, composition with
creditors, or in cases of enforcement of title into Licensed Technology and the
Licensed Rights, the respective license terminates with immediate effect.

(4)      In the event that ANADYS at any time shall directly or indirectly
merge, acquire or otherwise join with, or come under direct or indirect control
or direction of any other entity, ANADYS shall take into account EMBLEM's due
interest and shall inform EMBLEM prior to taking a decision.

                                   ARTICLE 11
                              TERM AND TERMINATION

(1)      This agreement expires upon expiration of the last of the Licensed
Patents or any earlier date as the parties mutually agree upon.

(2)      Both parties may terminate this agreement for important reasons
(Kundigung aus wichtigem Grund) as there are - but not limited to -- material
breach of contract,

<PAGE>

ANADYS TECHNOLOGY LICENSE AGREEMENT

                                                                    Page 9 of 13

or dissolution or bankruptcy of the other party. The termination has to be
effected in writing by registered letter to the other party. The letter shall be
deemed received after seven days of dispatch if sent to the last known address
of the other recipient. The party responsible for breach of the agreement may
affect a remedy to cure the breach within (90) days from receipt of notification
of termination from the other party.

(3)      Material breach of contract includes but is not limited to breach of
         Articles 2(4), 5(1), or 6(6) of this agreement.

(4)      The right to ANADYS to use the Licensed Technology, the Licensed
         Patents and to all other items acquired under this agreement cease.

                                   ARTICLE 12
                                   ARBITRATION

(1)      Any dispute arising out of, or in connection with, the agreement shall
be exclusively settled by a panel of three arbitrators under the rules
(Schiedsgerichtsordnung) of the Deutsche Institution fur Schiedsgerischtsbarkeit
e.V. unless otherwise specified below. The procedures shall be governed in
analogous application of the German Ordinance of Civil Procedure
(Zivilprozessordnung) then in effect unless otherwise specified below.

(2)      Each party shall name one arbitrator. The two arbitrators shall appoint
one presiding arbitrator who must be qualified as a judge under German law
(Befdhigung zum Richteramt). The arbitrators must speak and write the English
language unless the parties agree otherwise.

(3)      The party taking recourse to arbitration shall inform the other party
by registered letter stating subject and reasons of their claim, specifying a
motion and nominating one arbitrator. The defendant shall nominate an arbitrator
within three weeks of receipt of the claim. If the defendant fails to name an
arbitrator within this period or if the two arbitrators fail to appoint a
presiding arbitrator within three weeks of the appointment of the arbitrator
named by the defendant, the President of the Oberlandesgericht Karlsruhe shall
appoint the arbitrator or presiding arbitrator upon request of either party.

(4)      The arbitrators shall decide on the place of arbitration. In case they
reach no decision within two weeks after their appointment, the arbitration
shall take place in The Hague, Netherlands (or shall be determined by lottery).
The language of the proceedings shall be in English unless the parties agree
otherwise. Before the arbitration panel decides each party must have the
opportunity to express their views. An oral proceeding shall take place unless
the parties agree otherwise.

(5)      The arbitration panel shall fix the costs of the proceedings. The
arbitration decision is not subject to appeals.

<PAGE>

                                                                   Page 10 of 13

Done at Heidelberg the 9th day of January, 2001.

         Gabor M. Lamm                /s/ Kleanthis G. Xanthopoulos
         -------------------------    ------------------------------------
         EMBLEM                       ANADYS PHARMACEUTICALS, INC.

                   EMBLEM
          Technology Transfer GmbH
               Boxbergring 107
              69126 Heidelberg
                   Germany

         ANNEXES:
         ANNEX 1 LICENSED PATENTS
         ANNEX 2 LICENSED TECHNOLOGY
         ANNEX 3 OTHER PARTICIPATING INDIVIDUALS

<PAGE>

                                                                   Page 11 of 13

                                     ANNEX 1

                                LICENSED PATENTS

                                   [...***...]

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

                                                                   Page 12 of 13

                                     ANNEX 2

                               LICENSED TECHNOLOGY

Licensed Technology comprises

-    Methods and access to experimental results and data

-    Know-how and information

developed at EMBL in the field of RNA-RNA and RNA-protein interactions and
complexes, including but not limited to the following areas:

-    pre-mRNA splicing

-    mRNA polyadenylation

-    RNA transport

-    mRNA translation

-    mRNA turnover

-    nucleo-cytoplasmic transport.

and licensed under article 2 of the agreement.

<PAGE>

ANADYS TECHNOLOGY LICENSE AGREEMENT

                                                                   Page 13 of 13

                                     ANNEX 3

                         OTHER PARTICIPATING INDIVIDUALS

Peer Bork              120,000 shares of restricted common stock

[...***...]            [...***...]

                                             ***CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                 AMENDMENT TO THE "TECHNOLOGY LICENSE AGREEMENT"
                              DATED JANUARY 9, 2001

                                     BETWEEN

         EMBL ENTERPRISE MANAGEMENT TECHNOLOGY TRANSFER GMBH ("EMBLEM")

                                       AND

                     ANADYS PHARMACEUTICALS, INC. ("ANADYS")

1.       ANADYS and EMBLEM agree to replace the wording of Article 3(4) by the
         following wording:

         "ANADYS shall direct and control the filing, prosecution and
         maintenance of the Licensed Patents or Licensed Technology at its own
         expense for the duration of the license. ANADYS shall retain patent
         counsel reasonably acceptable to EMBLEM to conduct such prosecution.
         ANADYS shall provide to EMBLEM, and EMBLEM shall be entitled to review
         and comment upon, any documents related to and required for obtaining
         patent protection; provided that EMBLEM shall convey such comments
         within a reasonable time period. The above includes all documents to be
         filed or received from the applicable patent offices relating to the
         prosecution of the Licensed Patents or Licensed Technology, and other
         correspondence relating to such prosecution efforts, excluding
         privileged correspondence. ANADYS's patent counsel shall use diligent
         efforts to incorporate all reasonable comments of EMBLEM regarding such
         prosecution. ANADYS will assume the costs of, as well as retain any
         damages recovered in, an action for infringement or misappropriation of
         Licensed Patents or of Licensed Technology. EMBLEM will bring actions
         to protect the Licensed Patents or Licensed Technology at Anadys's
         request. If it becomes necessary to join EMBLEM as a party to an action
         to protect the Licensed Patents or Licensed Technology, EMBLEM agrees
         to join such an action, with the reasonable costs to be borne by
         ANADYS. If ANADYS decides not to further prosecute or maintain any of
         the patent applications or patents mentioned in or covered by Licensed
         Patents or Licensed Technology (including foreign or national phase
         counterparts thereof) including any patent rights involved in an appeal
         or patents involved in an opposition proceedings (referred to herein as
         "Available Rights"), ANADYS shall so advise EMBLEM in time to enable
         EMBLEM to take all appropriate actions to further prosecute or maintain
         any of the Available Rights if EMBLEM desires to do so, and unless
         impracticable, shall provide such notice at least sixty (60) days in
         advance of any filing or response deadlines with the applicable patent
         office(s). All Available Rights for which EMBLEM takes all appropriate
         actions to further prosecute or maintain, will return to EMBLEM
         (referred to herein as "EMBLEM Rights") subject to the Right of First
         Refusal

<PAGE>

         described in the following four sentences. If EMBLEM desires at any
         time to grant to a third party any license to any EMBLEM Rights, then
         EMBLEM shall provide Anadys with written notice of its intention,
         identifying the EMBLEM Rights proposed to be licensed and the identity
         of the proposed licensee (provided that disclosure of the identity of
         the proposed licensee would not render EMBLEM in breach of its express
         confidentiality obligations with such proposed licensee) and describing
         the terms under which EMBLEM proposes to license such rights. Anadys
         shall have sixty (60) days from the date such notice is given to agree
         to license EMBLEM Rights offered to a third party set forth in the
         notice under the same terms specified in the notice, by giving written
         notice to EMBLEM. In the event that ANADYS fails to exercise its right
         of first refusal within the sixty (60) day period, EMBLEM shall be free
         to license such rights to such proposed licensee (on not more favorable
         terms or conditions than those offered to Anadys) following the written
         disclosure to Anadys. At no time shall EMBLEM grant any license with
         respect to EMBLEM Rights to any third party on terms more favorable to
         the licensee than those last offered to Anadys.

2. Anadys and EMBLEM agree to add a new Article 1(7) as follows:

"Intellectual Property Information" means the following, in the Field: (1)
inventions, patents, patent applications and statutory invention registrations,
including reissues, continuations, continuations-in-part, divisions, extensions
and reexaminations thereof, and (2) such other technical information, data and
technology accessible to EMBLEM and/or EMBL concerning methods or techniques
developed by or held by EMBLEM and/or EMBL, which will be provided to ANADYS
under the restrictions of the Confidential Disclosure Agreement between the
Parties dated _____________.

3. ANADYS and EMBLEM agree to substitute in Articles 2 (2) and 2 (3), the
defined term "Intellectual Property Information" in all places where the defined
term "Intellectual Property" is used.

4. ANADYS waives any and all rights under Article 2(2) and Article 2(3)
to access and license Intellectual Property as defined in Article 1(6) to the
extent such information has not been and is not included in the definition of
Intellectual Property Information under Article 1 (7).

5. All other terms and conditions of the Technology License Agreement shall
remain the same and in full force and effect.

The Parties acknowledge that Sections 2, 3 and 4 of this Amendment are intended
only to correct a technical defect in EMBLEM's ability to provide know-how under
Article 2(2) and Article 2(3), with access to Intellectual Property as it is
defined in Article 1(6), and this Amendment provides for EMBL and EMBLEM to make
Intellectual Property Information, as more accurately defined above, available
to ANADYS for the purposes set forth in Article 2. At no time have the Parties
altered their original intent which is to provide ANADYS with exclusive and
first priority access to Intellectual Property

<PAGE>

Information in the Field developed in the EMBL groups of the Founders and first
priority access to Intellectual Property Information developed in the Field at
EMBL, in order to allow ANADYS an opportunity to license relevant technology for
research and commercial purposes.

Heidelberg, Germany the 14th day of November, 2002.

/s/ Gabor M. Lamm                     /s/ Kleanthis G. Xanthopoulos
------------------------------        ----------------------------------------
Gabor Lamm, Managing Director         Kleanthis G. Xanthopoulos, President & CEO
EMBLEM                                ANADYS PHARMACEUTICALS, INC.

<PAGE>

                  *** CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
                  DOCUMENT (INDICATED BY ASTERISKS) HAS BEEN OMITTED AND FILED
                  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
                  PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER 17
                  C.F.R. SECTIONS 200.80(B)(4), 200.83 AND 230.406.

               AMENDMENT #2 TO THE "TECHNOLOGY LICENSE AGREEMENT"
                              DATED JANUARY 9, 2001

                                     BETWEEN

         EMBL ENTERPRISE MANAGEMENT TECHNOLOGY TRANSFER GMBH ("EMBLEM")

                                       AND

                     ANADYS PHARMACEUTICALS, INC. ("ANADYS")

1.       ANADYS and EMBLEM agree to replace the wording of Article 5(1) by the
         following wording:

         "As consideration in full for the grant of the license under this
         agreement, ANADYS shall grant to i) EMBL ii)EMBLEM Technology Transfer
         GmbH and iii) certain other participating individuals as listed on
         Annex 3, a total of 1,649,413 shares of restricted Common Stock of
         ANADYS Pharmaceuticals, Inc. The grant to EMBL includes without
         limitation, all shares of restricted Common Stock of ANADYS, Inc. which
         ANADYS has designated for the Founders and which EMBL will assign to
         the Founders by mutual agreement between EMBL and the Founders
         following the entry into force of this Agreement. ANADYS will deliver
         the shares to the EMBLEM and the other individuals within 30 days
         following receipt of the payment of the nominal cost of the shares."

2.       Annex 3 is revised to delete reference to [...***...].

3.       All other terms and conditions of the Technology License Agreement
shall remain the same and in full force and effect.

Heidelberg, Germany the 9th day of September, 2003.

         /s/ Gabor M. Lamm                      /s/ Kleanthis G. Xanthopoulos
         --------------------                   -------------------------------
         Gabor M. Lamm, Ph.D.                   Kleanthis G. Xanthopoulos, Ph.D.
         Managing Director                      President & CEO
         EMBLEM                                 Anadys Pharmaceuticals, Inc.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]